Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 14/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847586 | 0.92 | MAPK8 (0.45) | MAPK8MAPK9JAK3JAK1SYK | |
| SCHEMBL848330 | 0.92 | MAPK8 (0.45) | MAPK8MAPK9JAK3JAK1SYK | |
| SCHEMBL2100940 | 0.92 | MAPK8 (0.45) | MAPK8MAPK9JAK3JAK1SYK | |
| SCHEMBL847497 | 0.89 | SYK (0.45) | JAK3SYKJAK2 | |
| SCHEMBL848652 | 0.86 | KDM4E (0.43) | JAK3SYKJAK2 | |
| SCHEMBL847840 | 0.83 | SYK (0.41) | JAK3SYKJAK2 | |
| SCHEMBL27800495 | 0.79 | MAPK8 (0.42) | MAPK8MAPK9JAK3JAK1PIM1 | |
| SCHEMBL846834 | 0.79 | MAPK8 (0.41) | MAPK8JAK1PIM1PIM2SYK | |
| SCHEMBL847031 | 0.79 | BTK (0.39) | JAK3SYKJAK2 | |
| SCHEMBL847489 | 0.77 | OPRK1 (0.45) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2148862-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. Hoffmann-Roche AG (CH) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009015917-A2 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008138920-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | MAPK9, MAPK10, MAPK1 | MAPK8 12/4885MAPK9 1/4885JAK3 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.